Malignant neoplasm of prostate
|
0.110 |
GeneticVariation
|
disease |
GWASDB |
Multiple loci identified in a genome-wide association study of prostate cancer.
|
18264096 |
2008 |
Body mass index procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association scans identified CTNNBL1 as a novel gene for obesity.
|
18325910 |
2008 |
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association with bone mass and geometry in the Framingham Heart Study.
|
17903296 |
2007 |
Bone Mineral Density Test
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association with bone mass and geometry in the Framingham Heart Study.
|
17903296 |
2007 |
Finding of body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association scans identified CTNNBL1 as a novel gene for obesity.
|
18325910 |
2008 |
Memory performance
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
A genome-wide survey and functional brain imaging study identify CTNNBL1 as a memory-related gene.
|
22105620 |
2013 |
Obesity
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In case-control studies neither of the CTNNBL1 variants showed association with overweight, obesity or morbid obesity (rs6013029: Odds Ratio (OR)(overweight) = 1.02 [0.90-1.16], OR(obesity) = 1.09 [0.95-1.25], OR(morbidobesity) = 1.26 [0.91-1.74]; rs6020846: OR(overweight) = 1.05 [0.93-1.18], OR(obesity) = 1.13 [1.00-1.28], OR(morbidobesity) = 1.17 [0.86-1.61]).
|
19245693 |
2009 |
Obesity
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We found no evidence for an association of the reported variants in CTNNBL1 with early onset obesity or increased BMI.
|
19228371 |
2009 |
Impaired cognition
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
17% of human unique orthologues of mouse NAP genes are known loci for cognitive dysfunction.
|
31371714 |
2019 |
Atrial Fibrillation
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Univariate analysis showed that the AP-MT group was older (P<0.001), more often had atrial fibrillation (P<0001), and had a higher ASPECTS (P<0.006 and P<0.002) compared with the NAP-MT group and NAP-IVTMT groups, respectively.
|
29602862 |
2018 |
Malocclusion
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Generalized linear models were used to quantify within and among sibship variances while controlling for sex, age, and severity of malocclusion (FMA, ANB, AOBO, overjet, NAP) as covariates.
|
9082853 |
1997 |
Obesity, Morbid
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In case-control studies neither of the CTNNBL1 variants showed association with overweight, obesity or morbid obesity (rs6013029: Odds Ratio (OR)(overweight) = 1.02 [0.90-1.16], OR(obesity) = 1.09 [0.95-1.25], OR(morbidobesity) = 1.26 [0.91-1.74]; rs6020846: OR(overweight) = 1.05 [0.93-1.18], OR(obesity) = 1.13 [1.00-1.28], OR(morbidobesity) = 1.17 [0.86-1.61]).
|
19245693 |
2009 |
Parkinson Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our results reveal that A53T α-synuclein (oligomers or aggregates) leads to the inhibition of mitochondrial trafficking, which can be rescued by NAP, suggesting the involvement of microtubule disruption in the pathophysiology of Parkinson's disease.
|
27866262 |
2017 |
Malignant neoplasm of prostate
|
0.110 |
Biomarker
|
disease |
BEFREE |
Label-free quantification of EVs was performed to identify differentially expressed proteins between PCa and NAP.
|
31018022 |
2019 |
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effect of NAP on Abeta and tau pathology using a transgenic mouse model that recapitulates both aspects of AD.
|
17478890 |
2007 |
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
Addressing Alzheimer's disease tangles: from NAP to AL-108.
|
19874271 |
2009 |
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
Thus, aluminum ions may increase the risk for neurotoxicity in AD, and the use of NAP is suggested as a treatment to provide additional protection against the effects of aluminum ions, via EEA1 and PI3KR2, associated with sorting and processing of the AD amyloid precursor protein (APP) through the endosomal system.
|
30987727 |
2019 |
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
Genome-wide association scans identified CTNNBL1 as a novel gene for obesity.
|
18325910 |
2008 |
Diabetic Retinopathy
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, deepened characterization of NAP action mechanism on hyperglycemic-inflammatory damage may be useful to develop a new strategy to prevent retinal damage during DR.
|
30374973 |
2019 |
Diabetic Retinopathy
|
0.020 |
Biomarker
|
disease |
BEFREE |
More recently, we have shown that a small peptide derived from the activity-dependent neuroprotective protein (ADNP), known as NAP, counteracts damages occurring during progression of diabetic retinopathy by modulating HIFs/VEGF pathway.
|
28436035 |
2018 |
Impaired cognition
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, the combination of NAP and standard of care Risperidone in humans may protect against language disturbances associated with negative and cognitive impairments in schizophrenia.
|
26553741 |
2015 |
Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site
|
0.020 |
Biomarker
|
disease |
BEFREE |
To detect and evaluate the antibodies against Helicobacter pylori (H pylori) neutrophil-activating protein (HP-NAP) in patients with gastric cancer and other gastroduodenal diseases.
|
19452583 |
2009 |
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Spliceosome-associated factor CTNNBL1 promotes proliferation and invasion in ovarian cancer.
|
28501461 |
2017 |
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
LHGDN |
Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer.
|
19148501 |
2009 |
Tauopathies
|
0.020 |
Biomarker
|
group |
BEFREE |
Here, we examined the potential preferential interaction of NAP with 3R vs. 4R Tau, toward personalized treatment of tauopathies.
|
30865715 |
2019 |